During the past decade, Japanese Red Cross Society Himeji Hospital conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 4 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 4 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Japanese Red Cross Society Himeji Hospital" #1 sponsor was "Amgen" with 2 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Incyte Corporation" with 2 trials sponsored and "Bioverativ, a Sanofi company" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Japanese Red Cross Society Himeji Hospital" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Japan Blood Products Organization" with 1 trials as a collaborator, "Japanese Gynecologic Oncology Group" with 1 trials as a collaborator and "Korean Gynecologic Oncology Group" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Japanese Red Cross Society Himeji Hospital" are "Epithelial Ovarian Cancer" (2 trials), "Myelofibrosis" (2 trials), "Post Essential Thrombocythemia Myelofibrosis" (2 trials), "Post Polycythemia Vera Myelofibrosis" (2 trials) and "Primary Myelofibrosis" (2 trials). Many other conditions were trialed in "Japanese Red Cross Society Himeji Hospital" in a lesser frequency.

Most popular intervention types in "Japanese Red Cross Society Himeji Hospital" are "Drug" (16 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "placebo" (3 trials), "Atezolizumab" (2 trials), "Baricitinib" (2 trials) and "parsaclisib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Japanese Red Cross Society Himeji Hospital" are 13 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Japanese Red Cross Society Himeji Hospital". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Japanese Red Cross Society Himeji Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Japanese Red Cross Society Himeji Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".